廣告
香港股市 已收市
  • 恒指

    17,021.31
    +16.34 (+0.10%)
     
  • 國指

    6,010.64
    -5.87 (-0.10%)
     
  • 上證綜指

    2,890.90
    +4.16 (+0.14%)
     
  • 滬深300

    3,409.29
    +10.02 (+0.29%)
     
  • 美元

    7.8066
    +0.0005 (+0.01%)
     
  • 人民幣

    0.9282
    +0.0025 (+0.27%)
     
  • 道指

    40,589.34
    +654.27 (+1.64%)
     
  • 標普 500

    5,459.10
    +59.88 (+1.11%)
     
  • 納指

    17,357.88
    +176.16 (+1.03%)
     
  • 日圓

    0.0505
    +0.0001 (+0.10%)
     
  • 歐元

    8.4741
    +0.0082 (+0.10%)
     
  • 英鎊

    10.0430
    +0.0110 (+0.11%)
     
  • 紐約期油

    76.44
    -1.84 (-2.35%)
     
  • 金價

    2,385.70
    +32.20 (+1.37%)
     
  • Bitcoin

    68,214.57
    +1,259.12 (+1.88%)
     
  • CMC Crypto 200

    1,380.37
    +49.77 (+3.74%)
     

Immunovant Could Potentially Be An M&A Target, Writes Analyst

  • Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Overweight rating and a price target of $30.

  • The company's pipeline includes batoclimab (IMVT-1401) and IMVT-1402, fully human, monoclonal antibodies targeting the neonatal fragment crystallizable receptor (FcRn).

  • Batoclimab has demonstrated its potential to reduce immunoglobulin G (IgG) antibodies that cause inflammation, while IMVT-1402 has also demonstrated profound IgG antibody reduction in animal studies.

  • Related: Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say.

  • Expected positive data readouts beginning in 2023+ from batoclimab and IMVT-1402 trials could drive shares higher, potentially narrowing the valuation gap between IMVT's market cap and its competitors, such as Argenyx SE (NASDAQ: ARGX).

  • Additionally, IMVT could attract potential strategic interest, as evidenced by Johnson & Johnson's (NYSE: JNJ) 2020 acquisition of anti-FcRn company Momenta Pharma for $6.5 billion.

  • IMVT's parent company Roivant Sciences Ltd (NASDAQ: ROIV), indicated in its 3Q22 earnings call that it would take a commercial view of any potential M&A inquiry relating to the company.

  • Price Action: IMVT shares are down 3.79% at $17.89 on the last check Wednesday.

Latest Ratings for IMVT

Date

Firm

Action

From

To

Dec 2021

Wells Fargo

Initiates Coverage On

Equal-Weight

Nov 2021

HC Wainwright & Co.

Maintains

Buy

Aug 2021

Baird

Downgrades

Outperform

Neutral

View More Analyst Ratings for IMVT

廣告

View the Latest Analyst Ratings

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Immunovant Could Potentially Be An M&A Target, Writes Analyst originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.